Cancer immunotherapies
by design™
iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.
At iTeos, we specialize in targeted immunotherapies for people living with cancer.
We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.
As a responsible company, we are committed to building Environmental, Social and Governance (ESG) principles into how we operate to create sustainable value for society and all of our stakeholders.
Our pipeline
Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.
The following information provides an overview of our dynamic pipeline of cancer therapy development. Studies underway are grouped by our primary drug therapies, and listed out by combination with other treatments. Indications for each combination under study, along with the current and planned phases of each study, are included.
iTeos drug trials move through five phases:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
iTeos drug trials move through five phases:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Following is a list of drug combinations currently under study with:
EOS-448
as well as the indication for each.
drug combo and indication:
+ dostarlimab | 1L NSCLC PDL1high
status of study phases:
Phase 3, planned
drug combo and indication:
+ dostarlimab | 1L NSCLC PDL1high | NCT05565378
status of study phases:
Phase 2, active trial ID NCT05565378
drug combo and indication:
+ dostarlimab | 1L HNSCC PDL1high / low | TIG-006
status of study phases:
Phase 2, active, trial ID TIG-006
drug combo and indication:
+ dostarlimab + chemotherapy | 1L mNSCLC | TIG-006
status of study phases:
Phase 1, active, trial ID TIG-006
drug combo and indication:
+ dostarlimab + CD96 | Advanced Malignancies | NCT03739710
status of study phases:
Phase 1, active, trial ID NCT03739710
drug combo and indication:
+ dostarlimab + PVRIG | Advanced Malignancies | NCT05277051
status of study phases:
Phase 1, active, trial ID NCT05277051
drug combo and indication:
Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma | TIG-007
status of study phases:
Phase 2, active, trial ID TIG-007
Following is a list of drug combinations currently under study with:
Inupadenant
as well as the indication for each.
drug combo and indication:
Monotherapy | High Biomarker | IO-001
status of study phases:
Phase 2, active, trial ID IO-001
drug combo and indication:
+ chemotherapy | Post-IO Chemo-naive NSCLC | A2A-005
status of study phases:
Phase 2, active, trial ID A2A-005
Following is a list of drug combinations currently under study with:
EOS-984
as well as the indication for each.
drug combo and indication:
Monotherapy | Advanced Malignancies
status of study phases:
Phase 1, planned
Studies with dark backgrounds are active. Studies with light backgrounds are planned.
There has never been a better time to work at iTeos.
As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.
Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.
Latest press releases
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new…
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provide…
– 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and…
